Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Share-based Compensation (2016 - 2025)

Haemonetics (HAE) has 17 years of Share-based Compensation data on record, last reported at $7.8 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 5.05% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $31.6 million, up 5.04%, while the annual FY2025 figure was $29.6 million, 4.6% up from the prior year.
  • Share-based Compensation reached $7.8 million in Q4 2025 per HAE's latest filing, up from $7.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.3 million in Q2 2025 and bottomed at $5.1 million in Q2 2022.
  • Average Share-based Compensation over 5 years is $7.0 million, with a median of $7.0 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: dropped 28.31% in 2022, then surged 38.47% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $6.0 million in 2021, then grew by 25.29% to $7.5 million in 2022, then dropped by 3.66% to $7.2 million in 2023, then rose by 13.81% to $8.2 million in 2024, then fell by 5.05% to $7.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $7.8 million in Q4 2025, $7.6 million in Q3 2025, and $9.3 million in Q2 2025.